$SSII
SS Innovations International, Inc. Stock $ssii

$ssii Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000121390022054262 Filed on September 06, 2022

Income Statement

Concept	2020 Q4	2020	2019
Revenue	$0.00		$0.00
YoY Change
Cost Of Revenue	$812.2K	$812.2K	$2.510M
YoY Change	-67.64%	-67.64%
Gross Profit	-$812.2K	-$812.2K	-$2.510M
YoY Change	-67.64%	-67.64%
Gross Profit Margin
Selling, General & Admin	-$612.1K	$287.7K	$752.0K
YoY Change		-61.74%	-19.42%
% of Gross Profit
Research & Development	$1.000K	$3.000K	$60.87K
YoY Change	-77.78%	-95.07%	124.36%
% of Gross Profit
Depreciation & Amortization	$9.360K	$37.43K	$37.70K
YoY Change	-9.39%	-0.72%	93.73%
% of Gross Profit
Operating Expenses	-$611.1K	$1.103M	$812.9K
YoY Change	-35.35%	35.68%	-15.36%
Operating Profit	-$201.1K	-$1.915M	-$3.323M
YoY Change	-87.15%	-42.36%
Interest Expense	-$80.00	$1.059K	-$19.74K
YoY Change	-98.57%	-105.36%	-33000.0%
% of Operating Profit
Other Income/Expense, Net	-$20.70K	-$21.75K	-$19.74K
YoY Change		10.2%
Pretax Income	-$221.8K	-$1.125M	-$3.386M
YoY Change	-86.25%	-66.78%	252.59%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$221.8K	-$1.125M	-$3.386M
YoY Change	-86.25%	-66.78%	252.59%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.05	-$0.16
Diluted Earnings Per Share	-$8.151K	-$0.05	-$157.2K
COMMON SHARES
Basic Shares Outstanding		23.37M shares	21.54M shares
Diluted Shares Outstanding		23.37M shares	21.54M shares

Balance Sheet

Concept	2020 Q4	2020	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$160.7K	$160.7K	$28.47K
YoY Change	464.49%	464.49%	-20.3%
Cash & Equivalents	$160.7K	$160.7K	$28.47K
Short-Term Investments
Other Short-Term Assets	$2.290K	$2.290K	$6.290K
YoY Change	-63.59%	-63.59%	7.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$163.0K	$163.0K	$34.76K
YoY Change	368.87%	368.93%	-16.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$38.21K	$38.21K	$84.64K
YoY Change	-54.86%	-54.86%	139.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$115.5K	$115.5K
YoY Change
Total Long-Term Assets	$154.9K	$154.9K	$97.76K
YoY Change	58.42%	58.42%	-5.89%
TOTAL ASSETS
Total Short-Term Assets	$163.0K	$163.0K	$34.76K
Total Long-Term Assets	$154.9K	$154.9K	$97.76K
Total Assets	$317.9K	$317.9K	$132.5K
YoY Change	139.86%	139.87%	-8.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$131.7K	$131.7K	$141.4K
YoY Change	-6.86%	-6.86%	1311.38%
Accrued Expenses	$188.7K	$860.2K	$596.9K
YoY Change	-68.38%	44.12%	81.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$90.00K
YoY Change	-100.0%	-100.0%	500.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.187M	$1.187M	$1.196M
YoY Change	-0.74%	-0.74%	165.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.187M	$1.187M	$1.196M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.187M	$1.187M	$1.196M
YoY Change	-0.74%	-0.74%	165.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$6.994M
YoY Change	19.16%
Common Stock	$6.024M
YoY Change	32.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$869.0K	-$869.1K	-$1.063M
YoY Change
Total Liabilities & Shareholders Equity	$317.9K	$317.9K	$132.5K
YoY Change	139.86%	139.87%	-8.88%

Cashflow Statement

Concept	2020 Q4	2020	2019
OPERATING ACTIVITIES
Net Income	-$221.8K	-$1.125M	-$3.386M
YoY Change	-86.25%	-66.78%	252.59%
Depreciation, Depletion And Amortization	$9.360K	$37.43K	$37.70K
YoY Change	-9.39%	-0.72%	93.73%
Cash From Operating Activities	-$5.920K	-$90.54K	-$424.1K
YoY Change	-95.07%	-78.65%	-4.33%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$4.000K	-$50.12K
YoY Change	-100.0%	-92.02%	112.64%
Acquisitions
YoY Change
Other Investing Activities	-$40.00K	-$40.00K
YoY Change
Cash From Investing Activities	-$40.00K	-$44.00K	-$50.12K
YoY Change	-260.0%	-12.21%	112.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$39.49K
YoY Change			97.45%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	206.0K	$266.8K	467.0K
YoY Change	120.29%	-42.87%	833.98%
NET CHANGE
Cash From Operating Activities	-5.920K	-$90.54K	-424.1K
Cash From Investing Activities	-40.00K	-$44.00K	-50.12K
Cash From Financing Activities	206.0K	$266.8K	467.0K
Net Change In Cash	160.0K	$132.2K	-7.240K
YoY Change	-10840.27%	-1926.45%	-98.26%
FREE CASH FLOW
Cash From Operating Activities	-$5.920K	-$90.54K	-$424.1K
Capital Expenditures	$0.00	-$4.000K	-$50.12K
Free Cash Flow	-$5.920K	-$86.54K	-$374.0K
YoY Change	-95.92%	-76.86%	-10.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21535656	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23372299	shares
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
CY2019	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2019	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2020	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware		usd
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Entity File Number EntityFileNumber	333-216054
CY2020	dei	Entity Registrant Name EntityRegistrantName	AVRA MEDICAL ROBOTICS, INC
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3478854
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	3259 Progress Drive
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 114
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Orlando
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32826
CY2020	dei	City Area Code CityAreaCode	(407)
CY2020	dei	Local Phone Number LocalPhoneNumber	956-2250
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39197099	shares
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	160709	usd
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	28474	usd
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2290	usd
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	6290	usd
CY2020Q4	us-gaap	Assets Current AssetsCurrent	162999	usd
CY2019Q4	us-gaap	Assets Current AssetsCurrent	34764	usd
CY2020Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	98592	usd
CY2019Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	119592	usd
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	60385	usd
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34954	usd
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38207	usd
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84638	usd
CY2020Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	115542	usd
CY2020Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	36122	usd
CY2019Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	36122	usd
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	35000	usd
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23000	usd
CY2020Q4	us-gaap	Other Assets OtherAssets	1122	usd
CY2019Q4	us-gaap	Other Assets OtherAssets	13122	usd
CY2020Q4	us-gaap	Assets Assets	317870	usd
CY2019Q4	us-gaap	Assets Assets	132524	usd
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	131719	usd
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	141417	usd
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	671500	usd
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	492825	usd
CY2019	avmr	Proceeds From Sba ProceedsFromSBA		usd
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	188700	usd
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	104040	usd
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	195000	usd
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	367500	usd
CY2019Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	90000	usd
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1186919	usd
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1195782	usd
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25721971	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25721971	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21857218	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21857218	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	2572	usd
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	2186	usd
CY2020Q4	avmr	Common Stock Liability Common Stock To Be Issued CommonStockLiabilityCommonStockToBeIssued	289697	shares
CY2019Q4	avmr	Common Stock Liability Common Stock To Be Issued CommonStockLiabilityCommonStockToBeIssued	128909	shares
CY2020Q4	avmr	Common Stock Liabilities Par Value CommonStockLiabilitiesParValue	0.0001
CY2019Q4	avmr	Common Stock Liabilities Par Value CommonStockLiabilitiesParValue	0.0001
CY2020Q4	avmr	Common Stock Liability CommonStockLiability	100925	usd
CY2019Q4	avmr	Common Stock Liability CommonStockLiability	254564	usd
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	6021201	usd
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	4549058	usd
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6993747	usd
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5869066	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-869049	usd
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1063258	usd
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	317870	usd
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	132524	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3000	usd
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60874	usd
CY2020	avmr	Compensation Expense CompensationExpense	812190	usd
CY2019	avmr	Compensation Expense CompensationExpense	2509792	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	287737	usd
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	752018	usd
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	43548	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	1102927	usd
CY2019	us-gaap	Operating Expenses OperatingExpenses	3366232	usd
CY2020	avmr	Gain On Forgiveness Of Ppp Loan GainOnForgivenessOfPPPLoan	-4630	usd
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	-25331	usd
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	6	usd
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	7	usd
CY2020	us-gaap	Interest Expense InterestExpense	1059	usd
CY2019	us-gaap	Interest Expense InterestExpense	19748	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21754	usd
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19741	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1124681	usd
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3385973	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-1124681	usd
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-3385973	usd
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23372299	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21535656	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-1124681	usd
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-3385973	usd
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	37431	usd
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	37702	usd
CY2019	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	43548	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	434180	usd
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1070369	usd
CY2019	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1732177	usd
CY2019	avmr	Concellation Of Common Stock ConcellationOfCommonStock	312500	usd
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	-25331	usd
CY2020	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	4630	usd
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	16221	usd
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-4000	usd
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	460	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	537829	usd
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	374811	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90540	usd
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-424105	usd
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	40000	usd
CY2019	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	122	usd
CY2020	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	4000	usd
CY2019	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	50000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-44000	usd
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-50122	usd
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	130200	usd
CY2019	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	352500	usd
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	-65000	usd
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	75000	usd
CY2020	avmr	Proceeds From Sba ProceedsFromSBA	4630	usd
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	194845	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2100	usd
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	39485	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	266775	usd
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	466985	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	132235	usd
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7242	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28474	usd
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35716	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	160709	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28474	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1059	usd
CY2019	us-gaap	Interest Paid Net InterestPaidNet	3527	usd
CY2019	avmr	Equipment Acquisition Included In Accounts Payable EquipmentAcquisitionIncludedInAccountsPayable	25000	usd
CY2020	avmr	Related Party Note Payable Converted To Common Stock RelatedPartyNotePayableConvertedToCommonStock	302700	usd
CY2020	avmr	Stock Issued For Website And Services StockIssuedForWebsiteAndServices	45000	usd
CY2020	us-gaap	Stock Issued1 StockIssued1	170000	usd
CY2020	avmr	Stock Issued For Equipment StockIssuedForEquipment	25000	usd
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-223037	usd
CY2019	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1070369	usd
CY2019	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	16221	usd
CY2019	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1507686	usd
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	39485	usd
CY2019	avmr	Stock Issued During Periods Value Issued For Services StockIssuedDuringPeriodsValueIssuedForServices	224491	usd
CY2019	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	312500	usd
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-3385973	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-1063258	usd
CY2020	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	412789	usd
CY2020	avmr	Stock Issued During Periods Value Issued For Services StockIssuedDuringPeriodsValueIssuedForServices	11449	usd
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	29921	usd
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	302700	usd
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	195089	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2100	usd
CY2020	avmr	Stock Issued During Period Value Private Placement StockIssuedDuringPeriodValuePrivatePlacement	194842	usd
CY2020	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	170000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-1124681	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-869049	usd
CY2020	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2020	us-gaap	Property Plant And Equipment Cost Capitalization PropertyPlantAndEquipmentCostCapitalization	$75,000
CY2020Q4	avmr	Percentage Financed By The Seller PercentageFinancedByTheSeller	1	pure
CY2020Q4	us-gaap	Collateralized Agreements CollateralizedAgreements	0	usd
CY2020	avmr	Equipment Description EquipmentDescription	After making several payments, the Company settled with the vendor due to issues with equipment, and was relieved of the $25,000 balance owed as of first quarter 2020. The total amount paid of $50,000 represents the actual cost.
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.25
CY2019Q3	avmr	Employee Agreement Term EmployeeAgreementTerm	P48M
CY2020	avmr	Stockholders Deficit StockholdersDeficit	869049	usd
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company regularly evaluates estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates made by management.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its principal cash balance in a financial institution. These balances are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2020 and 2019, $0 were in excess of the FDIC insured limit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2020Q4	avmr	Fdic Insured FDICInsured	250000	usd
CY2020Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2019Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2020	us-gaap	Intermediate Life Plants Useful Life IntermediateLifePlantsUsefulLife	P3Y
CY2019Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2019-09-29
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	37500	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2643635	shares
CY2019Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	51740	usd
CY2020Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	471825	usd
CY2019Q4	us-gaap	Collateralized Agreements CollateralizedAgreements	0	usd
CY2020Q4	avmr	Shares Issued Price Per Shares SharesIssuedPricePerShares	1.5
CY2020Q4	avmr	Notes Total NotesTotal	202700	usd
CY2020Q4	avmr	Total Units TotalUnits	202700	shares
CY2020Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	810800	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	1013500	shares
CY2020Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.4
CY2020Q3	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	17700	usd
CY2020	avmr	Exercised Options Shares ExercisedOptionsShares	390000	shares
CY2020Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.25
CY2020Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	100000	usd
CY2020Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	1000000
CY2020Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1000000	shares
CY2020Q1	avmr	Common Stock Per Share CommonStockPerShare	0.1
CY2020Q4	avmr	Payroll Protection Loan Amount PayrollProtectionLoanAmount	4630	usd
CY2018	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2019-12-31
CY2019Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2019-12-31
CY2019Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2019-09-11
CY2019Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2019-09-14
CY2019Q1	avmr	Number Of Warrants Purchase NumberOfWarrantsPurchase	12500	shares
CY2019Q1	avmr	Strike Price StrikePrice	1.25
CY2019Q1	avmr	Warrant Expiration Period WarrantExpirationPeriod	P3Y
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4259040	usd
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2019	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	894398	usd
CY2020	us-gaap	Gain Loss On Sale Of Leased Assets Net Operating Leases GainLossOnSaleOfLeasedAssetsNetOperatingLeases	221827	usd
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q1	avmr	Number Of Shares Issued Upon Compensation NumberOfSharesIssuedUponCompensation	218000	shares
CY2017Q4	us-gaap	Share Price SharePrice	2
CY2018Q3	avmr	Number Of Common Stock Sold NumberOfCommonStockSold	16000	shares
CY2018Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	20000	usd
CY2018Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	400	shares
CY2019Q1	avmr	Shares Value SharesValue	115050	shares
CY2019Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.25
CY2019Q2	avmr	Shares Value SharesValue	95050	shares
CY2019Q3	avmr	Shares Value SharesValue	79672	shares
CY2019Q3	avmr	Shares Value SharesValue	600000	shares
CY2019Q4	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	250000	shares
CY2020Q4	avmr	Description Of Avra Issued An Aggregate DescriptionOfAVRAIssuedAnAggregate	On November 6, 2020, AVRA issued an aggregate 256,027 Units (“Units”) at a price of $1.00 per Unit in a private offering (the “Offering”) to four “accredited investors.” Each Unit consisted of (a) four shares of our common stock (“Shares”); (b) a three-year warrant to purchase five Shares at an exercise price of $0.40 per Share; and (c) a 0.00008749_% limited liability company membership interest in Avra Air, LLC (“Avra Air”), a development stage company, which interest may be put to the Company at the option of the investor for a period of two years from issuance, in exchange for one Share. As a result of the foregoing, the investors were issued an aggregate of 1,024,108 Shares, warrants to purchase 1,280,135 Shares and a 22.4% limited liability company membership interest in Avra Air, LLC.
CY2020Q4	avmr	Commitment To Sell CommitmentToSell	135000	shares
CY2020Q4	avmr	Commitment To Sell Units CommitmentToSellUnits	135000	usd
CY2020Q4	avmr	Promissory Notes Value PromissoryNotesValue	25000	usd
CY2020Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	1027	usd
CY2020Q4	avmr	Commitment Units CommitmentUnits	26027	shares
CY2020Q4	avmr	Number Of Shares Issued Upon Compensation NumberOfSharesIssuedUponCompensation	321489	shares
CY2020Q4	avmr	Shares For A Stock Option Exercised SharesForAStockOptionExercised	21000	shares
CY2020Q4	avmr	Exercise Price Per Share ExercisePricePerShare	0.1
CY2020	avmr	Shares Of Common Stock SharesOfCommonStock	1810800	shares
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2016Q3	avmr	Employment Agreements Description EmploymentAgreementsDescription	On August 1, 2016, the Company entered into a three-year Employment Agreement with its Vice President of Global Business Development. The agreement provides for an annual salary of $96,000 per year, increasing to $144,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 100,000 shares vested on each yearly anniversary.
CY2020	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-05-01
CY2019Q3	us-gaap	Salaries And Wages SalariesAndWages	15000	usd
CY2020Q4	us-gaap	Public Utilities Property Plant And Equipment Vehicles PublicUtilitiesPropertyPlantAndEquipmentVehicles	500	usd
CY2020Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	1000000	shares
CY2020Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.25
CY2020	avmr	Lease Description LeaseDescription	The Company occupies office and laboratory space in Orlando, Florida under a lease agreement that expired on July 31, 2018. Effective August 1, 2018 and expiring July 31, 2019, the Company signed a new agreement, with monthly payments of $1,829.25 plus applicable sales tax. Effective August 1, 2019, the Company signed a year lease agreement, provides that the Company pay insurance, maintenance and taxes with a monthly lease expense of $2,454.75 plus applicable sales tax. Effective January 15, 2020, the Company amended its August 1, 2019 lease agreement reducing its monthly lease payment to $2,223 plus applicable sales tax. On April 30, 2020, the rent due under our lease agreement had been reduced by 50% for the months of April and May, 2020. On July 17, 2020, the Company signed a lease that was effective August 1, 2020 through July 31, 2021, which provides that the Company pay insurance, maintenance and taxes with a monthly lease expense of $1,474.17 plus applicable sales tax. Either party may cancel the agreement at any time with 30 days’ notice.
CY2020Q4	avmr	Private Offering Description PrivateOfferingDescription	October 26, 2020, subsequently invested an additional $45,000 on May 3, 2021 in this same Unit funding thus receiving an additional 180,000 Shares, a warrant to purchase 225,000 Shares and a put option for 45,000 Shares.
CY2021Q4	avmr	Shares Of Common Stock SharesOfCommonStock	45000	shares
CY2021Q4	us-gaap	Share Price SharePrice	0.1
CY2021Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	315200	usd
CY2020	avmr	Issued Discount IssuedDiscount	0.10	pure
CY2020	avmr	Conversion Amount ConversionAmount	100000000	usd
CY2020	avmr	Convertible Notedescription ConvertibleNotedescription	the Company offered and sold to a single accredited investor, a $1,000,000 one-year convertible promissory note (the “Convertible Note”). The Convertible Note will have the same interest rate and payment terms as the Cardio Note and otherwise be substantially similar to the Cardio Note, provided, however, that the Convertible Note does not have an original issue discount. Further, upon consummation of the Transaction (if and when it is consummated) the Convertible Note will automatically convert into a number of AVRA Shares determined by dividing the principal amount of the Convertible Note by $100 million and multiplying such number expressed as a percentage by the number of AVRA Shares issued to Dr. Sudhir and the other shareholders of the SSI Parties (if any) upon closing of the Transaction. The Company may offer and sell up to an aggregate principal amount of $5,000,000 in Convertible Notes in order to fund the Interim Financing.
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2020	avmr	Equipment Acquisition Included In Accounts Payable EquipmentAcquisitionIncludedInAccountsPayable		usd
CY2019	avmr	Related Party Note Payable Converted To Common Stock RelatedPartyNotePayableConvertedToCommonStock		usd
CY2019	avmr	Stock Issued For Website And Services StockIssuedForWebsiteAndServices		usd
CY2019	us-gaap	Stock Issued1 StockIssued1		usd
CY2019	avmr	Stock Issued For Equipment StockIssuedForEquipment		usd
CY2020Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	2.000000	usd
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001676163
CY2020Q2	dei	Entity Public Float EntityPublicFloat	0	usd

Files In Submission

Name	View Source	Status
0001213900-22-054262-index-headers.html	Edgar Link	pending
0001213900-22-054262-index.html	Edgar Link	pending
0001213900-22-054262.txt	Edgar Link	pending
0001213900-22-054262-xbrl.zip	Edgar Link	pending
avmr-20201231.xsd	Edgar Link	pending
f10k2020ex31-1_avramedical.htm	Edgar Link	pending
f10k2020ex32-1_avramedical.htm	Edgar Link	pending
f10k2020_avramedical.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
avmr-20201231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
avmr-20201231_lab.xml	Edgar Link	unprocessable
avmr-20201231_pre.xml	Edgar Link	unprocessable
avmr-20201231_cal.xml	Edgar Link	unprocessable
f10k2020_avramedical_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SSII
SS Innovations International, Inc. Stock $ssii

2020 Q4 Form 10-K Financial Statement

#000121390022054262 Filed on September 06, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSII SS Innovations International, Inc. Stock $ssii

2020 Q4 Form 10-K Financial Statement

#000121390022054262 Filed on September 06, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSII
SS Innovations International, Inc. Stock $ssii